Introduction

This report analyses both quantitatively and qualitatively the unbranded generics industry, the Top 10 generics companies by unbranded generics sales, the Top five therapy areas and the major North American, European, Asia Pacific and Latin American markets.

Scope of this research

• Evaluation of the unbranded generics market from 2004-08 in terms of sales.
• Country and region specific analysis of the generics market in terms of sales.
• Therapy area analysis including company and product level breakdown by sales.
• Qualitative discussion of the key issues impacting the generics industry including future outlook.
• Performance analysis of the Top 10 generics companies from 2004-08 including analysis of growth strategies employed.

Research and analysis highlights

Increased government expenditure, higher levels of public debt and budget deficits have put the spotlight on healthcare cost containment. Reducing healthcare costs through promotion of generics is expected to be a key growth driver for the generics industry.

The pharmaceuticals industry is seeing a shift from brand defense strategies and lifecycle management based predominantly on patent protection and innovation of follow-on products. Value is now being created from patent expiry through the R&D-Generics business model including authorized generics and in-house generics.

A drastic reduction in M&A activity has been seen since the global financial crisis took hold. Restricted credit and changes in strategic focus by companies towards paying down debt has facilitated this.

Key reasons to purchase this research

• Understand the generic pharmaceutical market dynamics.
• Learn about issues driving and resisting growth for generics companies.
• Gain insight into growth strategies employed by the Top 10 generics players.
• Target geographic focus through detailed analysis of countries and regions.
• Gain insight into the M&A strategies behind recent major deals.